Indian officials probe whether safety lapses led to children dying from cough syrup

A spoonful of cough syrup. THE CANADIAN PRESS/Graeme Roy

CHENNAI - Indian officials are investigating whether safety lapses in the supply of a pharmaceutical ingredient were responsible for contaminating cough syrup that has killed at least 24 children in recent months, according to three people familiar with the matter.

The three health and drug safety officials from Tamil Nadu state told Reuters they believe the solvent used to make a batch of Coldrif cough syrup could have been contaminated with a toxic chemical around the time it was supplied to the drugmaker, Sresan Pharmaceutical Manufacturer.

Sresan acquired 50 kg of the propylene glycol solvent from local chemicals distributor Sunrise Biotech on March 25, which had purchased it the same day from Jinkushal Aroma, a small company that makes fragrance blends for liquid detergents and other chemicals, according to interviews with the suppliers and an Oct. 3 investigation report by the Tamil Nadu pharmaceutical regulator, exclusively seen by Reuters.

The Tamil Nadu Drugs Control Department didn’t respond to repeated requests for comment about its investigation.

Authorities have said the Coldrif syrup was heavily contaminated with a known industrial toxin, diethylene glycol. They are investigating how the chemical was added to the solvent, which is used in cough syrup as a base for dissolving its active ingredients.

The fatalities, which began in September, have revived concerns about safety standards in India’s US$50 billion pharmaceutical sector, which was tarnished by the deaths of more than 140 children in Africa and Central Asia in 2022 and 2023 from Indian-made cough syrups made with contaminated solvents.

In the wake of those deaths, New Delhi had pledged to improve quality controls.

Indian health officials say DEG is sometimes fraudulently or unintentionally used in medicines in place of pricier PG. Ingesting high levels of it has been linked to acute kidney damage and death in children.

Reuters is reporting details for the first time about the focus of the Indian investigation, as well as breaches in global pharmaceutical safety practices in the delivery of the chemicals to Sresan.

Sresan’s manufacturing licence has been revoked and its founder G. Ranganathan is in custody. Efforts to contact representatives at Sresan’s corporate office and Ranganathan’s home were unsuccessful. Reuters was unable to identify a legal representative for Ranganathan.

The Central Drugs Standard Control Organization, which oversees pharmaceuticals federally, directed questions to India’s health ministry, which in turn referred Reuters to a government statement saying it was conducting more inspections of drug facilities and reviewing pediatric use of cough syrups.

Chemical makers typically deliver PG solvents to clients in sealed containers to avoid contamination, but Sunrise confirmed to Reuters that it had repackaged the solvent without a seal before delivering it.

India’s Drugs and Cosmetics Act prohibits the sale and handling of pharmaceutical-grade ingredients like medicinal PG by entities that do not have drug licences.

Neither Jinkushal nor Sunrise have licences for handling pharmaceutical-grade ingredients, the two wholesale distributors confirmed to Reuters. Their owners said they weren’t aware the PG they had sold would be used to make medication.

Both Sunrise operator Vipul Jain and Jinkushal owner Jitender Vishwakarma said they did not handle highly toxic DEG and had no knowledge about how the solvent might have been contaminated.

Reuters was unable to establish how the contamination occurred or who was responsible.

Inspections conducted by the state regulator after the deaths found hundreds of “critical” and “major” violations at Sresan’s factory outside the southern city of Chennai, including storing products in “unhygienic conditions” and “falsification of data,” according to the Oct. 3 report. The regulator did not, however, link those breaches directly to the deaths.

Repackaged chemicals

The PG that Sresan told inspectors it used was produced by South Korean manufacturer SK picglobal, according to a certificate of analysis shared by Jinkushal and Sunrise with investigators, reviewed by Reuters.

The certificate included the manufacturing date of the PG, as well as specifics about its chemical contents. Reuters couldn’t independently verify the accuracy of the contents though an SK picglobal spokesperson said the copy seen by the news agency appeared to be authentic.

SK picglobal exported the solvent in a sealed 215 kg barrel to an Indian distributor, who sold it to Jinkushal.

Jinkushal’s Vishwakarma said he broke the seals and repackaged the solvent in his store before selling some of it to chemicals distributor Sunrise.

Sunrise’s Jain said he then transported the chemical to Sresan in two containers without tamper-proof seals because the drugmaker had not wanted the entire original 215 kg of supply.

The SK picglobal spokesperson said the company strictly prohibits repacking or redistribution of its products

Asked if such restrictions were included in its contracts of sale, the company said it has told customers in meetings that it doesn’t “guarantee the quality of products that have been re-packed or arbitrarily subdivided for sale.” It did not provide further details.

History of violations

Sresan had been previously penalized by authorities, with its founder imprisoned for a day in 2020 and 2022 due to concerns about his products, before being issued a fine, according to four officials familiar with the matter. They did not provide documentary evidence for the penalties.

Tamil Nadu’s health minister told lawmakers last month that Sresan had been penalized in 2021 and 2023 for “minor violations,” without providing specifics.

Despite Sresan’s track record and regulations that require annual checks, the drugmaker’s factory had not been inspected since 2023, said two state health officials.

Reuters could not independently confirm when Sresan had been last inspected before the deaths.

(Reporting by Krishna N. Das, Rishika Sadam and Praveen Paramasivam in Chennai; Additional reporting by Jennifer Rigby in London, Joyce Lee in Seoul and Aditya Kalra and Arpan Chaturvedi in New Delhi; Editing by Katerina Ang)